Xeris Biopharma to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference
January 06 2022 - 7:00AM
Business Wire
Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical
company developing and commercializing unique therapies for patient
populations in endocrinology, neurology, and gastroenterology,
today announced that Paul R. Edick, Chairman and Chief Executive
Officer of Xeris Biopharma, will present an overview of the company
and highlight recent events, including the FDA approval of
Recorlev®, at the H.C. Wainwright BioConnect 2022 virtual
conference being held January 10-13, 2022.
The on-demand presentation will be available beginning January
10, 2022 at 7:00 a.m. E.T. through the investors section on the
Company's website at www.xerispharma.com.
About Xeris Biopharma
Xeris (Nasdaq: XERS) is a biopharmaceutical company developing
and commercializing unique therapies for patient populations in
endocrinology, neurology, and gastroenterology. Xeris has two
commercially available products; Gvoke®, a ready-to-use liquid
glucagon for the treatment of severe hypoglycemia, and Keveyis®,
the first and only FDA-approved therapy for primary periodic
paralysis. In addition, Recorlev® was recently approved by the U.S.
Food and Drug Administration for the treatment of endogenous
Cushing’s syndrome. Xeris also has a robust pipeline of development
programs to extend the current marketed products into important new
indications and uses and bring new products forward using its
proprietary formulation technology platforms, XeriSol™ and
XeriJect™, supporting long-term product development and commercial
success.
Xeris is headquartered in Chicago, IL. For more information,
visit www.xerispharma.com, or follow us on Twitter, LinkedIn or
Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220106005180/en/
Investor Contact Allison Wey Senior Vice President,
Investor Relations and Corporate Communications
awey@xerispharma.com
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Jul 2023 to Jul 2024